Nursing Elites

1. A client with a history of deep vein thrombosis is prescribed enoxaparin. The nurse should monitor for which potential adverse effect?

• A. Increased risk of bleeding
• B. Decreased risk of bleeding
• C. Increased risk of infection
• D. Decreased risk of infection

Correct answer: A

Rationale: Enoxaparin is an anticoagulant that works by preventing blood clots. One of the potential adverse effects of enoxaparin is an increased risk of bleeding due to its anticoagulant properties. Therefore, the nurse should monitor the client for signs of bleeding, such as easy bruising, petechiae, or blood in stool or urine, to ensure timely intervention and prevent complications.

2. What side effect is a male client likely to experience while receiving furosemide 40mg by mouth?

• A. Difficulty starting urination
• B. Nosebleeds
• C. Muscle cramps
• D. Visual disturbances

Correct answer: C

Rationale: Muscle cramps are a common side effect of furosemide due to its impact on electrolyte levels, especially potassium. Furosemide is a loop diuretic that can lead to potassium depletion, resulting in muscle cramps as one of the manifestations of electrolyte imbalances. Therefore, choices A, B, and D are incorrect. Difficulty starting urination is not a common side effect of furosemide; nosebleeds and visual disturbances are not typically associated with this medication.

3. A client with a history of heart failure is prescribed carvedilol. The nurse should monitor for which potential side effect?

• A. Bradycardia
• B. Tachycardia
• C. Hypertension
• D. Hyperglycemia

Correct answer: A

Rationale: When a client is prescribed carvedilol, the nurse should monitor for bradycardia, a potential side effect of this medication. Carvedilol is a beta-blocker that can slow down the heart rate, so monitoring for signs of bradycardia is essential to prevent any adverse effects on the client's cardiovascular system. Tachycardia (Choice B) is less likely to occur with carvedilol since it primarily works to reduce heart rate. Hypertension (Choice C) and hyperglycemia (Choice D) are not common side effects associated with carvedilol.

4. Which action should be taken to assess for analgesic tolerance in a client who is unable to communicate?

• A. Review the client's laboratory values for changes in peak and trough levels of the analgesic
• B. Prolong the interval between analgesic medication doses and monitor the client's vital signs
• C. Observe the client for the presence of pain behaviors before the next analgesic dose is due
• D. Ask family members to report behaviors suggesting that the client's pain has returned

Correct answer: C

Rationale: In clients who are unable to communicate, observing for pain behaviors is crucial in assessing analgesic tolerance. Changes in pain behaviors can indicate if the current analgesic regimen is effective or if tolerance has developed. Therefore, closely observing the client for pain behaviors before the next analgesic dose helps healthcare providers evaluate the client's response to pain management. Reviewing laboratory values may not directly reflect analgesic tolerance. Prolonging the interval between doses and monitoring vital signs may not provide direct information on analgesic tolerance. Relying solely on family members to report pain behaviors may not be as accurate or immediate as observing the client directly.

5. A client with chronic kidney disease is prescribed darbepoetin alfa. The nurse should monitor for which potential side effect?

• A. Hypertension
• B. Hypotension
• C. Hyperkalemia
• D. Hyperglycemia

Correct answer: A

Rationale: The correct answer is A: Hypertension. Darbepoetin alfa, used to treat anemia in chronic kidney disease, can lead to hypertension as a side effect. This medication stimulates red blood cell production, which can increase blood pressure. Monitoring blood pressure regularly is crucial to detect and manage this potential adverse effect. Choices B, C, and D are incorrect because hypotension, hyperkalemia, and hyperglycemia are not commonly associated with darbepoetin alfa therapy in chronic kidney disease.

Similar Questions